Corporate Profile for Sepracor, dated Oct. 18, 1996.--(BUSINESS WIRE)--The following Corporate Profile is available for inclusion in your files. News releases for this client are distributed by Business Wire and also become part of the leading databases and information services. These include Dow Jones News/Retrieval, Bloomberg Financial Markets, Reuter Company Newsyear, Reuter Business Briefing, DataTimes, Nexis, Dialog, NewsNet, America OnLine, CompuServe, Delphi, Individual's HeadsUp and First!, Desktop Data's NewsEdge, UMI UMI University Microfilms International UMI United States Minor Outlying Islands (ISO Country code) UMI University of Miami UMI Universal Management Infrastructure (IBM) Data Courier, NewsBank, Information Access Company, Prodigy, Comtex, and many others. -0-
Published Date: Oct. 18, 1996
Company Name: Sepracor Inc.
Address: 111 Locke Drive
Marlborough, MA 01752-7231
Main Telephone
Number: 508/481-6700
Chief Executive
Officer: Timothy J. Barberich
Chief Financial
Officer: David P. Southwell
Investor Relations
Contact: Jean M. Devine
Business number: 508/357-7342
Home number: 508/369-7329
Public Relations
Contact: Jonae R. Barnes
Business number: 508/357-7342
Home number: 617/334-2440
Trading Symbol: SEPR
Industry: Pharmaceuticals
Company description: Sepracor Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : SEPR SEPR Senior Enlisted Performance Report ) is an emerging pharmaceutical company developing a portfolio of improved versions of existing drugs, primarily for the upper respiratory, urology and pain markets. Referred to as Improved Chemical Entities, or ICEs, these single-isomer or active-metabolite versions of drugs offer safety and/or efficacy benefits over their parent drugs. Sepracor has one drug with an approved NDA (Non Disclosure Agreement) An agreement signed between two parties that have to disclose confidential information to each other in order to do business. In general, the NDA states why the information is being divulged and stipulates that it cannot be used for any , six drug candidates in clinical development and several in preclinical study. The company has issued patents covering 15 ICEs and more than 25 patents pending for additional compounds. Key drugs in Sepracor's portfolio include: Upper Respiratory -- Fexofenadine (Allegra), an improved form of Seldane for allergy, received NDA approval in July 1996. -- R-albuterol, a purified version of the world's leading bronchodilator bronchodilator /bron·cho·di·la·tor/ (-di´la-ter) 1. expanding the lumina of the air passages of the lungs. 2. an agent which causes dilatation of the bronchi. for asthma, is in Phase III. -- Norastemizole, a differentiated metabolite of the nonsedating antihistamine antihistamine (ăn'tĭhĭs`təmēn), any one of a group of compounds having various chemical structures and characterized by the ability to antagonize the effects of histamine. , Hismanal, is in Phase I/II trials. -- R,R-eformoterol, a bronchodilator for asthma that offers the twin features of rapid onset of action onset of action Pharmacology The length of time needed for a medicine to become effective. See Therapeutic drug monitoring. and long duration, is in preclinical study. Urology -- S-oxybutynin, a therapy for urinary incontinence without anticholinergic anticholinergic /an·ti·cho·lin·er·gic/ (-ko?lin-er´jik) parasympatholytic; blocking the passage of impulses through the parasympathetic nerves; also, an agent that so acts. an·ti·cho·lin·er·gic n. side effects, is in Phase I/II clinical trials. Pain -- R-ketoprofen, a purified form of the analgesic, ketoprofen, is in Phase II clinical trials. -- S-fluoxetine, a purified version of Prozac, and potential prophylaxis for migraine, is in Phase II clinical trials. CONTACT: Sepracor |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion